Compare Ascendis Pharma A/S (ASND) vs Celestica Inc (CLS) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

CLS trades at $359.85, up 1.43% today, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with a 52.45% ROE and 6.95% net margin, supported by positive analyst sentiment and a $440.10 consensus price target. Recent leadership changes and raised revenue guidance to $19 billion highlight growth prospects in AI and cloud infrastructure.

Outlook remains positive driven by AI demand and earnings beats, but high valuation multiples (P/E 43.62) and competitive pressures pose risks. Investors should monitor Q2 2026 results on July 27, 2026, for confirmation of growth trajectory amid margin challenges noted by analysts.